A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

NCT06715241 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

77

Enrollment

OTHER

Sponsor class

Conditions

LOCALLY ADVANCED CERVICAL CANCERS

Interventions

COMBINATION_PRODUCT: combination of relatlimab and nivolumab wich are two immunotherapy treatments
OTHER: Nivolumab alone

Sponsor

ARCAGY/ GINECO GROUP